ZyVersa Therapeutics, Inc.

NasdaqCM ZVSA

ZyVersa Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024

ZyVersa Therapeutics, Inc. Net Cash Used For Investing Activities is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

ZyVersa Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 2.70 M, a 103.44% change year over year.
ZyVersa Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -78.45 M.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqCM: ZVSA

ZyVersa Therapeutics, Inc.

CEO	Mr. Stephen C. Glover
IPO Date	Feb. 11, 2022
Location	United States
Headquarters	2200 N. Commerce Parkway
Employees	7
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Key trends

Past 5 years